CompletedNCT05039489
This study is completed. It focuses on schizophrenia and currently lists study information in China.
SchizophreniaOtherFrom 18 Years to 45 Years
- Countries
- China
- Sponsor
- Central South University
- Condition
- Schizophrenia
CompletedNCT01932398
This study is completed. It focuses on ADHD and currently lists study information in the Netherlands.
ADHDOtherFrom 84 Months to 95 Months
- Countries
- Netherlands
- Sponsor
- Radboud University Medical Center
- Condition
- ADHD
CompletedNCT05137704
This study is completed in the United Kingdom. It focuses on ADHD.
ADHDOtherOver 18 Years
- Countries
- United Kingdom
- Sponsor
- Takeda
- Condition
- ADHD
CompletedNCT03666715
This study is completed in Portugal. It focuses on schizophrenia.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- Portugal
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Condition
- Schizophrenia
CompletedNCT05145413
This study is completed in the United States, in the United Kingdom, in Bulgaria, .... It is testing KarXT for schizophrenia.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States, United Kingdom, Bulgaria, ...
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Condition
- Schizophrenia
CompletedNCT04659161
This study is completed in the United States. It is testing KarXT for schizophrenia.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Condition
- Schizophrenia
CompletedNCT04738123
This study is completed in the United States and in Ukraine. It is testing KarXT for schizophrenia.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States, Ukraine
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Condition
- Schizophrenia
CompletedNCT02720263
This study is completed in the United States. It is testing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 for schizophrenia.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- United States
- Sponsor
- Astellas Pharma Global Development, Inc.
- Condition
- Schizophrenia
TerminatedNCT03669640
This study has public registry information in the United States, in Japan, in Spain, .... It is testing Effects of RO6889450 (Ralmitaront) for schizophrenia.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- United States, Japan, Spain, ...
- Sponsor
- Hoffmann-La Roche
- Condition
- Schizophrenia
CompletedNCT05919823
This study is completed in China. It is testing KarXT for schizophrenia.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- China
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Condition
- Schizophrenia
CompletedNCT05972044
This study is completed in the United States. It is testing solriamfetol for ADHD.
ADHDOtherFrom 18 Years to 55 Years
- Countries
- United States
- Sponsor
- Axsome Therapeutics, Inc.
- Condition
- ADHD
CompletedNCT03557931
This study is completed in the United States. It is testing Safety and Efficacy of ASP4345 for schizophrenia.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- United States
- Sponsor
- Astellas Pharma Global Development, Inc.
- Condition
- Schizophrenia
